Risk-adapted Omission of Systematic Cores in PI-RADS 3 Lesions Based on Prostate-specific Antigen Density, Biopsy Route, and Targeted Core Number: A Multicentre Cohort Study [0.03%]
基于前列腺特异性抗原密度、活检途径和靶向核心数量的PI-RADS 3病变的风险适应系统核心遗漏：一项多中心队列研究
Bogdan Adrian Buhas,Georges Mjaess,Romain Diamand et al.
Bogdan Adrian Buhas et al.
Background: Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions represent an intermediate-risk group for which the additional diagnostic value of systematic biopsy (SBx) after multiparametric magnetic ...
Reply to Kelly M. de Ligt, Sarah P. Psutka, and Laura S. Mertens's Letter to the Editor Re: Martino Pedrani, Alberto De Giorgi, Andrea Gallina, et al. When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.04.008 [0.03%]
关于Kelly M. de Ligt，Sarah P. Psutka和Laura S. Mertens致编辑信的回复：当患者拒绝根治性膀胱切除术时：在ICI/ADC围手术期整合三联疗法。《欧洲泌尿肿瘤学》在线发表。DOI:10.1016/j.euo.2026.04.008
Martino Pedrani,Alberto De Giorgi,Andrea Gallina et al.
Martino Pedrani et al.
Thibaut Long-Depaquit,Michael Baboudjian,Arthur Peyrottes et al.
Thibaut Long-Depaquit et al.
Cedric Peters,Romain Diamand,Paulus Kristanto
Cedric Peters
VI-RADS Score Performance in the Post-TURBT Setting: Exploring the Need for Modification [0.03%]
VI-RADS评分在TURBT术后应用中的表现：探讨修改的必要性
Ailin Dehghanpour,Martina Pecoraro,Gu-Mu-Yang Zhang et al.
Ailin Dehghanpour et al.
Background: The Vesical Imaging-Reporting and Data System (VI-RADS) was introduced to standardize bladder magnetic resonance imaging (MRI) interpretation, mainly in treatment-naïve patients. However, most patients underg...
FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting [0.03%]
尿路上皮癌中FGFR3检测：从患者识别到结果报告的最佳实践专家意见
Eva M Compérat,Arndt Hartmann,Yves Allory et al.
Eva M Compérat et al.
Context: Metastatic urothelial cancer (mUC) is associated with diverse genomic alterations, including frequent FGFR3 mutations that influence survival outcomes and treatment responses. Erdafitinib, a targeted therapy, has...
Re: Martino Pedrani, Alberto De Giorgi, Andrea Gallina, et al. When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.04.008 [0.03%]
马尔蒂诺·佩德拉尼，阿尔贝托·德·乔治，安德烈亚·加利纳等。当患者拒绝根治性膀胱全切术时：将三联疗法整合到围手术期ICI/ADC时代。Eur Urol Oncol. 在线发表。http://dx.doi.org/10.1016/j.euo.2026.04.008
Kelly M de Ligt,Sarah P Psutka,Laura S Mertens
Kelly M de Ligt
From metabolic benefit to survival benefit: The missing link for metformin in prostate cancer [0.03%]
从代谢获益到生存获益：二甲双胍治疗前列腺癌的缺失环节
Dries Develtere,Gaëtan Devos
Dries Develtere
Quality of Life After Postprostatectomy Radiotherapy: A TROG 08.03 RAVES Randomized Controlled Trial Substudy [0.03%]
术后放疗的生活质量: TROG 08.03 RAVES随机对照试验的亚研究
Justin Smith,Gill M Duchesne,Andrew Kneebone et al.
Justin Smith et al.
Background and objective: There is continued uncertainty about whether the timing of radiotherapy (RT) after radical prostatectomy (RP) affects toxicity. This study assesses differences in patient-reported quality of life...
Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making [0.03%]
尿路上皮膀胱肿瘤的分子分型：从肿瘤生物学角度出发进行临床决策
Constance Thibault,Hélène Blons,Yves Allory et al.
Constance Thibault et al.
Context: Bladder cancer ranks among the most common malignancies worldwide, with urothelial carcinoma as the predominant histological type. Its development from normal urothelium to non-muscle-invasive bladder cancer (NMI...